- Michael Carter | 10 August 2011
Approximately 50% of
American gay men said they were likely to use pre-exposure prophylaxis (PrEP), but few reported
that it would lead to a change in their risk behaviour, according to data ...
- Michael Carter | 01 August 2011
Patients whose CD4 cell count does not recover despite
achieving virologic control with HIV therapy require continued medical
attention, results of a large European study presented to the recent
International AIDS Society conference ...
- Liz Highleyman | 28 July 2011
People with hepatitis C virus (HCV) genotype 1b respond better to boceprevir and are less likely to develop drug resistance than those with genotype 1a, according to study findings reported ...
- Carole Leach-Lemens | 26 July 2011
Valaciclovir
used to suppress herpes simplex virus 2 (HSV-2) in HIV co-infected pregnant and
post-partum women in Nairobi, Kenya, slowed HIV disease progression and reduced
viral load in breast milk, according to researchers ...
- Gus Cairns | 26 July 2011
The anti-herpes drug valaciclovir (Valtrex, valacyclovir in the
US) produced a 17-fold (1.23 log) reduction in HIV viral load in Kenyan
patients not taking treatment, the sixth International AIDS Society conference (IAS ...
- Liz Highleyman | 26 July 2011
The
next-generation HIV integrase inhibitor dolutegravir (S/GSK1349572)
suppressed HIV viral load as well as efavirenz (Sustiva,
Stocrin) but caused fewer side-effects in a study of treatment-naive
patients, researchers reported at the
International AIDS Society Conference ...
- Roger Pebody | 26 July 2011
In Kenya,
Tanzania and Namibia, just 46% of HIV-positive women and 28%
of HIV-positive men have discussed family planning with a healthcare provider,
delegates were told at the International AIDS Society conference (IAS ...
- Roger Pebody | 25 July 2011
Researchers are investigating the impact of offering
financial incentives to people who are at risk of acquiring or passing on HIV,
the International AIDS Society conference (IAS 2011) in Rome heard last ...
- Carole Leach-Lemens | 25 July 2011
Extended use of nevirapine or
zidovudine and nevirapine in infants can reduce the risks of HIV transmission
through breastmilk by over 70%, Charles van der Horst reported in a late
breaker session at ...
- Michael Carter | 25 July 2011
A nucleoside-sparing
regimen based on raltegravir and ritonavir-boosted darunavir is as safe and
effective as a traditional nucleoside-based HIV treatment combination,
according to the results of a small US study presented to the ...
- Gus Cairns | 22 July 2011
A completed series of investigations into the iPrEx study of
tenofovir/FTC(Truvada) as pre-exposure prophylaxis (PrEP) has found that the drug
was 92% efficacious in preventing HIV infection amongst those who had detectable
drug ...
- Liz Highleyman | 22 July 2011
Lersivirine, an investigational
non-nucleoside reverse transcriptase inhibitor (NNRTI), lowered HIV viral load
about as well as efavirenz (Sustiva,
Stocrin) for people starting antiretroviral therapy for the first time,
researchers reported at the International AIDS ...
- Gus Cairns | 22 July 2011
A vaccine symposium held at the sixth International AIDS Society conference (IAS 2011) in Rome
heard how designers are slowly developing HIV vaccines designed to overcome
problems that had prevented the creation ...
- Roger Pebody | 21 July 2011
A two-year, seven-country study has
concluded that women using hormonal contraceptives, particularly injectable
forms, are at a greater risk both of acquiring HIV themselves and of passing it
on to a male sexual ...
- Theo Smart | 21 July 2011
“A nurse-led service
can deliver ART care as effectively as a doctor-driven one, and even improves
quality of care, but this pragmatic trial did not result in increased access
to ART,” said Lara ...
- Liz Highleyman | 21 July 2011
The
experimental HIV integrase inhibitor elvitegravir works as well as raltegravir
(Isentress) for treatment-experienced
people with extensive drug resistance, and was well tolerated overall,
according to data presented at the
sixth International AIDS Society conference ...
- Keith Alcorn | 20 July 2011
A 48-week course of antiretroviral treatment started within
six months of becoming infected modestly delays the need for lifelong treatment,
reported Dr Sarah Fidler of Imperial College, London, at the sixth
International AIDS ...
- Roger Pebody | 20 July 2011
The
ongoing roll-out of male circumcision in Orange Farm, South Africa, has succeeded in bringing the
proportion of men who are circumcised from 16 to 49% in three years, delegates
heard at the ...
- Liz Highleyman | 20 July 2011
Cognitive impairment remains common
amongst people with HIV and is linked to more severe immune deficiency and
absence of treatment, researchers reported at the International AIDS Society
Conference (IAS 2011) this week in ...
- Gus Cairns | 20 July 2011
Two consecutive sessions at the sixth International AIDS Society conference (IAS 2011) in Rome
yesterday were devoted, now we have convincing scientific data on the benefits
of treatment as prevention and PrEP, ...
Antiretroviral drug chartA one-page reference guide to the anti-HIV drugs licensed for use in the UK or European Union, with information on formulation, dosing, key side effects and food requirements.
Your next stepsA booklet with information for people who’ve just found
out they have HIV.
Coming soon: news from IAS 2019 05 July 2019The 10th International AIDS Society
conference (IAS 2019) is being held...
Those who are not seen are not heard 01 July 2019A commentary on Optimising the Impact of Key Population Programming...
The fight for access to abortion care in Europe 27 June 2019Access to
sexual and reproductive health and rights includes safe and...